左心耳封堵（LAAC）技术凭借优异的安全性和有效性，在卒中预防方面为大量房颤患者实现了高效且稳定的生活质量提升和长期预后改善。在过去的十 ...

近日，西安交通大学第二附属医院心血管病院王洪涛副主任心脏电生理团队，成功完成西北地区首例一站式FARAPULSE脉冲导管消融联合Watchman FLX左心耳封堵术，并顺利解决了1例复杂房扑的消融难题。手术后，两位患者均恢复至正常窦性心律，生命体征稳定。

11月16日，西安医学院第一附属医院心血管内科二病区、介入诊疗科团队成功完成了医院首例房颤Pulsed FA脉冲电场消融联合WATCHMAN ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

(RTTNews) - Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure (LAAC) Device.

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...